Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Genome-Trial-Results

More Like This

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

PR Newswire associated0

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer